Lyfius Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-11-2024
- Paid Up Capital ₹ 1.00 M
as on 17-11-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1,550.00 Cr
as on 17-11-2024
- Satisfied Charges ₹ 250.00 Cr
as on 17-11-2024
- Revenue %
(FY 2023)
- Profit -3838.60%
(FY 2023)
- Ebitda -46.22%
(FY 2023)
- Net Worth 110944.94%
(FY 2023)
- Total Assets 426.65%
(FY 2023)
About Lyfius Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1,550.00 Cr. The company has closed loans amounting to ₹250.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rama Krishna, Srinivasa Ilapakurthy, Santhanam Subramanian, and One other member serve as directors at the Company.
- CIN/LLPIN
U24299AP2020PTC116443
- Company No.
116443
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Nov 2020
- Date of AGM
29 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Lyfius Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rama Krishna  | Whole-Time Director | 25-Apr-2022 | Current |
| Srinivasa Ilapakurthy | Director | 02-Feb-2024 | Current |
| Santhanam Subramanian | Director | 16-Nov-2020 | Current |
| Nityananda Kambam | Director | Current |
Financial Performance of Lyfius Pharma.
Lyfius Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 3838.6% decrease in profit. The company's net worth Soared by an impressive increase of 110944.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lyfius Pharma?
In 2023, Lyfius Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Apitoria Pharma Private LimitedActive 7 years 1 monthSanthanam Subramanian and Nityananda Kambam are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 23 Sep 2024 | ₹150.00 Cr | Open |
Hdfc Bank Limited Creation Date: 31 Jul 2024 | ₹150.00 Cr | Open |
Others Creation Date: 30 Dec 2022 | ₹1,250.00 Cr | Open |
How Many Employees Work at Lyfius Pharma?
Lyfius Pharma has a workforce of 170 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lyfius Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lyfius Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
